Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASE1 | P07998 | 1/20 | 0.62 |
| ▸ | TK1 | P04183 | 5/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | ALB | P02768 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | TK2 | O00142 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15354282 | 1.00 | RNASE1 (0.62) | RNASE1TK1LMNATSHRALB | |
| SCHEMBL2056757 | 1.00 | RNASE1 (0.62) | RNASE1TK1LMNATSHRALB | |
| SCHEMBL25747162 | 1.00 | RNASE1 (0.62) | RNASE1TK1LMNATSHRALB | |
| SCHEMBL25797545 | 1.00 | RNASE1 (0.62) | RNASE1TK1LMNATSHRALB | |
| SCHEMBL24059196 | 1.00 | RNASE1 (0.62) | RNASE1TK1LMNATSHRALB | |
| SCHEMBL733403 | 1.00 | RNASE1 (0.62) | RNASE1TK1LMNATSHRALB | |
| SCHEMBL8424862 | 0.92 | RNASE1 (0.53) | RNASE1TK1LMNAALBPKM | |
| SCHEMBL8424863 | 0.92 | RNASE1 (0.53) | RNASE1TK1LMNAALBPKM | |
| SCHEMBL10079072 | 0.91 | TOP2A (0.54) | RNASE1TK1 | |
| SCHEMBL14788961 | 0.91 | TOP2A (0.54) | RNASE1TK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212204-A1 | REAGENTS AND THEIR USE FOR MODULAR ENANTIODIVERGENT SYNTHESIS OF C-P BONDS | THE SCRIPPS RESEARCH INSTITUTE | 2023-07-06 | — | — | US | disclosed |
| WO-2021234459-A9 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2022-02-03 | — | — | WO | disclosed |
| WO-2021234459-A2 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2021-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212204-A1 | REAGENTS AND THEIR USE FOR MODULAR ENANTIODIVERGENT SYNTHESIS OF C-P BONDS | PNKP, POLL, RNGTT | RNASE1 540/4885TK1 345/4885LMNA 3270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.